Navigation Links
Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
Date:12/3/2013

SAN DIEGO, Dec. 3, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) (the "Company"), a biopharmaceutical company focused on the treatment of obesity, today announced that it priced its offering of $100 million aggregate principal amount of convertible senior notes due 2020 (the "Notes").  The Notes were offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").  In connection with the offering of the Notes, the Company has granted the initial purchasers a 13-day option to purchase up to an additional $15 million aggregate principal amount of such Notes.

Upon conversion, the Notes will be settled in shares of the Company's common stock (together with cash in lieu of any fractional shares). However, if the Company receives stockholder approval in accordance with the Nasdaq Listing Standards, the Company will settle conversions of the Notes through payment or delivery, as the case may be, of cash, shares of Company's common stock or a combination thereof, at the Company's election.

The Notes will pay interest semi-annually at a rate of 2.75% per year. The Notes will mature on December 1, 2020, unless earlier repurchased or converted in accordance with their terms prior to such date. Prior to September 1, 2020, the Notes will be convertible at the option of holders only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the business day immediately preceding the maturity date. Holders of the Notes will have the right to require the Company to repurchase all or some of their Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of certain events. The conversion rate for the Notes will initially be 122.1
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
2. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
3. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
6. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
7. Orexigen Therapeutics to Present at Upcoming Conferences
8. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
9. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
11. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... , Opinion ... Decade , WASHINGTON, Dec. 9 On Tuesday, December 8, 2009, ... The Decade-2 Education Forum in ... science to America,s students and was sponsored by Amgen , a leading ...
... /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced ... Executive Officer, replacing Dr. Brad Popovich. , "We want to ... over the last four years. Brad has taken the Company ... period of time. Brad has also managed to recruit one ...
... ... Sciences Research Adopts the Genedata Screener® 7.0 Data Management Platform for High Throughput and ... ... a leading provider of advanced software solutions for drug discovery and life science research, ...
Cached Biology Technology:Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 2Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 3Sirius Genomics Announces Change in Leadership 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/12/2014)... 12, 2014 Crossmatch™, a leading provider of ... ® fingerprint readers have been deployed throughout Montparnasse ... Central Mexico . The bakery chain implemented the ... issues caused by employees clocking in for each other. ... readers, Montparnasse relied on paper timecards and a mechanical ...
(Date:11/10/2014)... shelves in early 2010, and people have used them ... be tossed into a washing machine without ever having ... though, has come with risks for young children. , ... found that from 2012 through 2013, U.S. poison control ... years of age swallowing, inhaling, or otherwise being exposed ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... in their own interests and do not cooperate ... severity of infection. The selfish behaviour ... treat antibiotic-resistant infections, according to research being presented ... today. Bacteria work together by using a ...
... TORONTO, ON - Widespread reports of a decline in the ... and speculation that pollination is also likely on the decline. ... long-term evidence of a downward trend in pollination, while also ... numbers may have declined at our research site, but we ...
... San Diego have discovered that a gene critical for programmed ... stem cells, a finding that could help to improve the ... chemotherapy or radiation therapy that kills cancer cells by inducing ... side effects for human cancer patients is the depletion of ...
Cached Biology News:Backstabbing bacteria: A new treatment for infection? 2Biologists find way to reduce stem cell loss during cancer treatment 2
... utility and flexibility press-to-seal silicone isolators can ... the researcher. They are available either pre-cut ... material that can be easily trimmed to ... and non-cytotoxic and can be used to ...
Request Info...
... turntable. Provides up to 30 minutes of walkaway time. Automatic Calibration. Five minute ... RS-232 port. ... ... ...
... • Holds 0.1 mL - 25 mL pipets ... pipets. Also accommodates most standard square or round pipet ... Has four compartments, each 76 mm W x 76 ... x 11 3/8 ins.). Overall dimensions: 89 mm W ...
Biology Products: